Abstract
Ribozymes are involved in strategies to block gene expression and have been used as agents against viral infections and cancer. Emphasis has been on studies using hairpin and hammerhead ribozymes. The uniqueness of ribozymes is that they posses multiple turnover allowing high efficiency as antiviral agents. Ribozymes have been directed to human immunodeficiency virus (HIV), hepatitis (B, C and E) and human papillomavirus (HPV), the cause of cervical cancer. The mode of action of antiviral ribozymes, their structure and their in vitro effectiveness as inhibitors of HIV, HBV, HCV, HEV and HPV is reviewed. Although ribozymes have been demonstrated as effective antivirals in cell culture and some animal models, clinical studies have been limited. Nevertheless, ribozymes remain as a viable alternative to antisense and RNA interference
Keywords: Ribozyme, catalytic RNA, antisense, ribonucleic acid, RNA, papillomavirus, AIDS, hepatitis virus, hepadnavirus, HIV, HPV
Letters in Drug Design & Discovery
Title: Utilization of Ribozymes as Antiviral Agents
Volume: 3 Issue: 6
Author(s): M. L. Benitez-Hess and L. M. Alvarez-Salas
Affiliation:
Keywords: Ribozyme, catalytic RNA, antisense, ribonucleic acid, RNA, papillomavirus, AIDS, hepatitis virus, hepadnavirus, HIV, HPV
Abstract: Ribozymes are involved in strategies to block gene expression and have been used as agents against viral infections and cancer. Emphasis has been on studies using hairpin and hammerhead ribozymes. The uniqueness of ribozymes is that they posses multiple turnover allowing high efficiency as antiviral agents. Ribozymes have been directed to human immunodeficiency virus (HIV), hepatitis (B, C and E) and human papillomavirus (HPV), the cause of cervical cancer. The mode of action of antiviral ribozymes, their structure and their in vitro effectiveness as inhibitors of HIV, HBV, HCV, HEV and HPV is reviewed. Although ribozymes have been demonstrated as effective antivirals in cell culture and some animal models, clinical studies have been limited. Nevertheless, ribozymes remain as a viable alternative to antisense and RNA interference
Export Options
About this article
Cite this article as:
Benitez-Hess L. M. and Alvarez-Salas M. L., Utilization of Ribozymes as Antiviral Agents, Letters in Drug Design & Discovery 2006; 3 (6) . https://dx.doi.org/10.2174/157018006777805521
DOI https://dx.doi.org/10.2174/157018006777805521 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Pharmaceutical Applications of the Benzylisoquinoline Alkaloids from Argemone mexicana L.
Current Topics in Medicinal Chemistry Total Synthesis and Bioactivity of ent-homospisulosine and N,O-diacetylhomoclavaminol A
Current Organic Chemistry Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Anticancer Peptides and Proteins: A Panoramic View
Protein & Peptide Letters The DNA-Binding and Bioactivity of Rare Earth Metal Complexes
Mini-Reviews in Medicinal Chemistry Recent Developments of Nanoparticles in the Treatment of Photodynamic Therapy for Cervical Cancer
Anti-Cancer Agents in Medicinal Chemistry Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Oncogenic MicroRNA-27a is a Target for Genistein in Ovarian Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry The BET-Bromodomain Inhibitor JQ1 Reduces Inflammation and Tau Phosphorylation at Ser396 in the Brain of the 3xTg Model of Alzheimer’s Disease
Current Alzheimer Research Editorial [Hot Topic: Tumor Immunology (Guest Editors: Bharat H. Joshi and Raj K. Puri)]
Current Molecular Medicine The Human Desmin Promoter Drives Robust Gene Expression for Skeletal Muscle Stem Cell-Mediated Gene Therapy
Current Gene Therapy Evaluation of Pregabalin Therapy in Peripheral Neuropathy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Radix Astragali (Astragalus): Latest Advancements and Trends in Chemistry, Analysis, Pharmacology and Pharmacokinetics
Current Organic Chemistry Surgical Management of Medullary Thyroid Carcinoma in Pediatric Age
Current Pediatric Reviews Targetting Esophageal and Gastric Cancers with Monoclonal Antibodies
Current Topics in Medicinal Chemistry microRNAs-based Predictor Factor in Patients with Migraine-ischemic Stroke
MicroRNA On the Relationship Between the Light/Dark Cycle, Melatonin and Oxidative Stress
Current Pharmaceutical Design Muscular Dystrophies: Histology, Immunohistochemistry, Molecular Genetics and Management
Current Pharmaceutical Design Truncated Lactoferricin Peptide Controls Cervical Cancer Cell Proliferation <i>via</i> lncRNA-NKILA/NF-κB Feedback Loop
Protein & Peptide Letters